This content is PDF only. Please click on the PDF icon to access.
Maintenance dialysis can be continued in patients with end-stage renal disease who have manifestations of human T-lymphotropic virus type lll/lymphadenopathyassociated virus (HTLV-III/LAV) [now known as the human immunodeficiency virus], including the acquired immunodeficiency syndrome, or who are positive for antibody to HTLV-III/LAV. These patients can be dialyzed in hospital-based or free-standing dialysis units using conventional infection-control precautions. Transmission of HTLV-III/LAV is adequately prevented by standard blood and body fluid precautions, and disinfection and sterilization procedures.
Recommendations for Providing Dialysis Treatment to Patients Infected with Human T-Lymphotropic Virus Type lll/Lymphadenopathy-Associated Virus. Ann Intern Med. 1986;105:558–559. doi: https://doi.org/10.7326/0003-4819-105-4-558
Download citation file:
Published: Ann Intern Med. 1986;105(4):558-559.
HIV, Infectious Disease, Nephrology, Renal Replacement Therapy.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use